<DOC>
	<DOCNO>NCT02845050</DOCNO>
	<brief_summary>Phase Ib/II study assess neo-adjuvant combination therapy vinflunine cisplatin follow radical cystectomy patient muscle-invasive bladder cancer ( JaNEO ) .</brief_summary>
	<brief_title>Phase Ib/II Study Assessing Neo-adjuvant Combination Therapy Vinflunine With Cisplatin Followed Radical Cystectomy Patients With Muscle-invasive Bladder Cancer ( JaNEO )</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>1 . Male female patient age ≥ 18 year ≤ 75 year legal capacity 2 . Signed write informed consent 3 . Histologically confirm muscleinvasive urothelial cell carcinoma bladder ( MIBC ) clinical T2T4a ( N0/Nx , M0 ) assess primary PDDguided TURB screen magnetic resonance imaging ( MRI ) 4 . Confirmed adequate complete resection visible tumor TURB accord current treatment guideline registration ; late TURB must do ≤ 8 week registration 5 . ECOG performance status 0 1 6 . Adequate bone marrow , renal hepatic function evidence follow : Absolute Neutrophil Count ≥ 2,000 mm3 ≤ 7,500 mm3 Hemoglobin ≥ 12 g/dL safety phase study ; study treatment proved adequate tolerate safety phase , threshold lower ≥ 10 g/dL accord decision study steer committee Platelet count ≥ 100,000 mm3 Serum albumin within normal range Serum total bilirubin ≤ 1.5 x upper limit normal ( ULN ) Transaminases ( ALT , AST ) ≤ 1.5 x ULN Creatinine clearance ≥ 60 mL/min , calculate base 24hmeasured creatinine clearance Serum Urea &lt; 25 mg/100 ml 7 . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition assess patient registration 8 . Electrocardiogram ( ECG ) without modification suggest high risk occurrence acute clinical event ( sign angina pectoris highrisk arrhythmia , etc . ) ; cardiologist consultation require , relevant abnormality observe screen ECGassessment 1 . Prior systemic chemotherapy kind malignancy ; prior intravesical chemotherapy treatment BCG allow 2 . Prior radiation pelvis prior radiation ≥ 30 % bone marrow 3 . Evidence lymph node ( N+ ) distant metastasis ( M1 ) screen MRI assessment , include know brain metastasis leptomeningeal involvement ( however , brainMRIscans require rule CNSinvolvement , unless clinical suspicion central nervous system ( CNS ) disease ) 4 . Other malignancy except adequately treat basal carcinoma skin , localized prostate cancer Gleason ≤ 6 , insitu cervix carcinoma tumor disease free interval ≥ 5 year 5 . Peripheral neuropathy Grade ≥ 2 NCI CTCAE v4.03 hear impairment Grade ≥ 2 NCI CTCAE v.4.03 6 . Any concurrent chronic system immune therapy previous organ allograft 7 . Weight loss &gt; 5 % within last 3 month registration 8 . Any serious illness medical condition include : Infection require systemic antiinfective therapy within last 2 week registration History cardiovascular disease might compromise safe administration cisplatin Dehydration require IV fluid substitution Any medical condition might control , e.g . patient unstable angina pectoris , myocardial infarction &lt; 6 month registration uncontrolled diabetes , congestive cardiac failure &gt; NYHA grade I 9 . Known hypersensitivity study drug drug similar chemical structure 10 . Treatment potent CYP3A4 inhibitor inductor ( e.g . ketoconazole , itraconazole , ritonavir , amprenavir , indinavir , rifampicine ) phenytoine ; replacement treatment alternative treatment option start study treatment acceptable , medically feasible ethically acceptable 11 . Treatment hexamethylmelamin , pyridoxine , penicillamine drug know potential affect efficacy cisplatin 12 . Treatment investigational anticancer therapy ≤ 30 day registration 13 . Pregnant lactate female patient female patient childbearing potential positive pregnancy test screen 14 . Women childbearing potential unwilling unable use acceptable method avoid pregnancy entire study period 6 month study 15 . Sexually active fertile men use effective birth control study 6 month study partner woman childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>neo-adjuvant</keyword>
	<keyword>vinflunine</keyword>
	<keyword>cisplatin</keyword>
	<keyword>radical cystectomy</keyword>
	<keyword>muscle-invasive bladder cancer</keyword>
	<keyword>JaNEO</keyword>
</DOC>